company background image
CYC

CyclopharmASX:CYC Stock Report

Market Cap

AU$166.2m

7D

7.9%

1Y

-21.6%

Updated

17 Oct, 2021

Data

Company Financials +
CYC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CYC Overview

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Cyclopharm
Historical stock prices
Current Share PriceAU$1.78
52 Week HighAU$1.55
52 Week LowAU$3.45
Beta0.58
1 Month Change0.28%
3 Month Change5.95%
1 Year Change-21.59%
3 Year Change72.82%
5 Year Change49.58%
Change since IPO-5.07%

Recent News & Updates

Jun 29
Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

One thing we could say about the covering analyst on Cyclopharm Limited ( ASX:CYC ) - they aren't optimistic, having...

Apr 27
Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

The share price of Cyclopharm Limited ( ASX:CYC ) has increased significantly over the past few years. However, the...

Shareholder Returns

CYCAU Medical EquipmentAU Market
7D7.9%-0.7%0.9%
1Y-21.6%-4.9%20.2%

Return vs Industry: CYC underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.

Return vs Market: CYC underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is CYC's price volatile compared to industry and market?
CYC volatility
CYC Beta0.58
Industry Beta0.57
Market Beta1

Stable Share Price: CYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CYC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198648James McBrayerhttps://www.cyclopharm.com.au

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. It offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.

Cyclopharm Fundamentals Summary

How do Cyclopharm's earnings and revenue compare to its market cap?
CYC fundamental statistics
Market CapAU$166.21m
Earnings (TTM)-AU$4.32m
Revenue (TTM)AU$20.39m

8.2x

P/S Ratio

-38.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYC income statement (TTM)
RevenueAU$20.39m
Cost of RevenueAU$4.74m
Gross ProfitAU$15.66m
ExpensesAU$19.98m
Earnings-AU$4.32m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.046
Gross Margin76.78%
Net Profit Margin-21.19%
Debt/Equity Ratio0%

How did CYC perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

-19%

Payout Ratio

Valuation

Is Cyclopharm undervalued compared to its fair value and its price relative to the market?

3.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CYC (A$1.78) is trading above our estimate of fair value (A$0.04)

Significantly Below Fair Value: CYC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CYC is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: CYC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYC is good value based on its PB Ratio (3.7x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Cyclopharm forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-4.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYC's revenue (11.4% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: CYC's revenue (11.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYC is forecast to be unprofitable in 3 years.


Past Performance

How has Cyclopharm performed over the past 5 years?

-63.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYC is currently unprofitable.

Growing Profit Margin: CYC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYC is unprofitable, and losses have increased over the past 5 years at a rate of 63.4% per year.

Accelerating Growth: Unable to compare CYC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: CYC has a negative Return on Equity (-9.75%), as it is currently unprofitable.


Financial Health

How is Cyclopharm's financial position?


Financial Position Analysis

Short Term Liabilities: CYC's short term assets (A$42.3M) exceed its short term liabilities (A$4.7M).

Long Term Liabilities: CYC's short term assets (A$42.3M) exceed its long term liabilities (A$5.3M).


Debt to Equity History and Analysis

Debt Level: CYC is debt free.

Reducing Debt: CYC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CYC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 54.4% each year


Dividend

What is Cyclopharm current dividend yield, its reliability and sustainability?

0.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CYC's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.27%).

High Dividend: CYC's dividend (0.56%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).


Stability and Growth of Payments

Stable Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CYC is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

James McBrayer (56 yo)

13.33yrs

Tenure

AU$1,186,588

Compensation

Mr. James S. McBrayer, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD880.72K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CYC's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: CYC's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.


Top Shareholders

Company Information

Cyclopharm Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cyclopharm Limited
  • Ticker: CYC
  • Exchange: ASX
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$166.207m
  • Shares outstanding: 93.37m
  • Website: https://www.cyclopharm.com.au

Number of Employees


Location

  • Cyclopharm Limited
  • 1 The Crescent
  • Unit 4
  • Kingsgrove
  • New South Wales
  • 2208
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.